Immunomodulation

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Retrieved on: 
Mercredi, avril 10, 2024
Cancer, Interleukin, Pembrolizumab, Merck & Co., Pancreatic serous cystadenoma, Tumor microenvironment, Immunoglobulin E, Patient, TILT, B cell, Potyvirus, Immunomodulation, AACR, Neoplasm, Merck, Ovarian cancer, Injection, Platinum, Pharmaceutical industry

HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • Analysis of biological samples revealed insights into mechanism of action, including an immunological profile potentially predictive of clinical response.
  • The results presented at AACR 2024, along with data from other ongoing trials, underscore the promise of TILT-123 as a novel cancer therapy.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

Retrieved on: 
Dimanche, avril 14, 2024
Inflammation, Congress, ECP, Blood, Cell death, EIA, Research, MRCP, Science, Medicine, Haematopoietic system, EBMT, Teaching hospital, Immunomodulation, Knowledge, Monocyte, Pharmaceutical industry

DUBLIN, April 14, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of the European Bone Marrow Transplant Meeting (EBMT), Europe's largest annual congress in blood and bone marrow transplantation and cellular therapies. In recognition of 30 years since clinicians first used ECP to successfully treat chronic GvHD,1 Mallinckrodt, provider of immunomodulatory therapy via Extracorporeal Photopheresis (ECP) and manufacturer of the world's only fully integrated, validated, ECP system, is pleased to mark this important milestone by this year dedicating the award to the study of ECP for cGvHD.

Key Points: 
  • Host Disease (cGvHD), this year's grant is to be dedicated to research in cGvHD --
    DUBLIN, April 14, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of the European Bone Marrow Transplant Meeting (EBMT), Europe's largest annual congress in blood and bone marrow transplantation and cellular therapies.
  • "Mallinckrodt has pioneered ECP immunomodulation through its THERAKOSTM CELLEXTM Photopheresis System and is pleased to support continued research that further contributes to this field of medicine," said Peter Richardson, MRCP (UK), Executive Vice President & Chief Scientific Officer.
  • Entries to the 2024 EIA Award will close on 1 September 2024.
  • This event will be presented by the GvHD Hub, and supported through an unrestricted educational grant from Therakos, Mallinckrodt.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mardi, mars 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Global Anterior Uveitis (Iritis) Drug Pipeline Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Mercredi, mars 6, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Acquisition, IOP, Macrophage, News, Route, Eye, Uveitis, Discovery, Risk, Administration, Clinical trial, Immunomodulation, NDA, NCE, Pharmaceutical industry

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anterior Uveitis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anterior Uveitis pipeline landscape.
  • A detailed picture of the Anterior Uveitis pipeline landscape is provided which includes the disease overview and Anterior Uveitis treatment guidelines.
  • The assessment part of the report embraces, in depth Anterior Uveitis commercial assessment and clinical assessment of the pipeline products under development.
  • Anterior Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Immunis Chairman Dr. Hans Keirstead is an Invited Speaker at the 2024 Brain Trust Conference

Retrieved on: 
Vendredi, février 23, 2024
Biotechnology, Pharmaceutical, Health, Therapy, Brain trust, Heart, Metabolism, Intelligence, Immunomodulation, Conference

Immunis, Inc. , a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead , will present at the exclusive 13D Brain Trust Conference in the Bahamas.

Key Points: 
  • Immunis, Inc. , a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead , will present at the exclusive 13D Brain Trust Conference in the Bahamas.
  • Brain Trust is a highly exclusive, invite-only event covering artificial intelligence, global technological advancements, innovative biotechnology, and unique investment opportunities.
  • Like its name, the Brain Trust Conference invites the world’s greatest minds to realize their visions for the world.
  • We thank the Brain Trust Conference for honoring Dr. Keirstead as a guest speaker and for including Immunis in the atmosphere of intellectual exchange to propel humanity forward.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
Lundi, février 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock

Retrieved on: 
Lundi, janvier 8, 2024
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Biometrics, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Roche, Risk, ACCURATE, Septic shock, Mortality, Disease, Blood, Incidence, Immunomodulation, Death, Intensive care medicine, Patient, Sepsis, Pharmaceutical industry

The ACCURATE trial design is built upon Phase 2 (ASTONISH) data that confirmed nangibotide’s strong efficacy and safety profile.

Key Points: 
  • The ACCURATE trial design is built upon Phase 2 (ASTONISH) data that confirmed nangibotide’s strong efficacy and safety profile.
  • This unique biomarker-guided approach allows for a single Phase 3 registration trial with a manageable number of subjects.
  • “Inotrem is now in a leading position to conduct a single Phase 3 registration trial in a prospectively defined population of septic shock patients that are at high risk of morbidity and mortality.
  • With nangibotide, Inotrem has developed a novel approach of immunomodulation targeting the TREM-1 pathway to restore appropriate inflammatory response, vascular function and improve post septic shock survival.

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Retrieved on: 
Mercredi, novembre 29, 2023
Immunotherapy, Food, U.S. FDA, IND, Biological activity, EMA, FDA, Research, Disease, Trial of the century, MBA, MD, SAB, POBA, Pharmacokinetics, Investigational New Drug, ATG, Immunomodulation, Type 1 diabetes, Patient, Safety, CTA, Pharmaceutical industry

SIOUX FALLS, S.D., Nov. 29, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for disease-modification of Type 1 Diabetes (T1D) through delaying the onset and/or progression of the disease, today announced that the first participants of a HUMAN trial (Fully HUman anti-thymocyte biologic in first-in-MAN clinical study) have been dosed in Australia. This Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with T1D. SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin being developed as a disease-modifying treatment to delay the onset and progression of T1D.

Key Points: 
  • SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin being developed as a disease-modifying treatment to delay the onset and progression of T1D.
  • In October 2023 , SAB received approval by the Australian Human Research Ethics Committee (HREC) to commence the Phase 1 clinical trial investigating safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of SAB-142.
  • More information about the Phase 1 clinical trial with SAB-142 (ACTRN:12623001089628) can be found here .
  • “We are grateful to partner with SAB on this Phase 1 investigation that will explore the therapeutic potential of a new, potentially best-in-class immunotherapeutic option for patients.”

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Retrieved on: 
Dimanche, novembre 26, 2023
DREAM, Prognosis, FDA, Endothelial dysfunction, Disease, Mortality, Person, Inflammation, Ageing, ODD, Heart, Immunomodulation, Ventricular septal defect, MSB, Growth, Patient, HLHS, Journal, Heart failure, MESO, Pharmaceutical industry

Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.

Key Points: 
  • Unfortunately, achievement of this objective is limited by the inability in most patients for the left ventricle to grow sufficiently to support the circulation to the body.
  • The FDA has authority to grant orphan drug (OD) designation to a drug or biological product to prevent, diagnose or treat a rare disease or condition, defined as any disease or condition that affects less than 200,000 persons in the United States.
  • An orphan drug designation (ODD) qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and the potential for seven years of market exclusivity after approval.
  • A rare pediatric disease designation (RPDD) demonstrates that the disease is serious or life-threatening and the manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents, and that the disease is a rare disease or condition.

NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC

Retrieved on: 
Mardi, décembre 19, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Spleen, Immunotherapy, Conference, TME, LSAM, American Conference, Flow cytometry, Blood, Mouse, Paclitaxel, Immunomodulation, Society, Poster, Safety, Lung cancer, NK, NMIBC, SITC, Vaccine

NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.
  • The poster was authored by clinical investigators Hiren Mehta , Abhishek Biswas , Sarah Wang , Jason Akulian , Christine Argento , et.al.
  • Summarizing presented data:
    The early phase lung cancer trial demonstrated safety and tolerability of intratumoral (IT) LSAM-PTX in combination with various concurrent therapies, including systemic immunotherapy.
  • Summarizing presented data:
    Immunophenotyping in 3 diverse tumor settings found commonalities in antitumor immunomodulation following local LSAM-DTX, including changes in T cells and MDSCs.